Medicaid Paid $5.15 Billion for Autism Therapy Since 2018. Fraud Charges Are Now Piling Up.

Since federal prosecutors charged two Minnesota autism clinic operators in May with allegedly billing Medicaid $46.6 million for therapy that was unnecessary or never delivered, scrutiny of the autism therapy industry has only grown. New Department of Health and Human Services provider data now shows just how big the money involved actually is.

Medicaid paid more than $5.15 billion between 2018 and 2024 under one of the primary billing codes for Applied Behavior Analysis therapy, according to HHS Medicaid provider spending data cited by Fox News. Three providers alone collected roughly $685 million of that total during the same period.

ABA therapy is widely used to help children with autism build communication, social and daily living skills through structured, one-on-one sessions. Most of the hands-on work is done by Registered Behavior Technicians, who complete a 40-hour training program and operate under the supervision of Board Certified Behavior Analysts, who design and oversee the treatment plans.

The Minnesota Case and the Billing Spike Problem

The Minnesota charges announced in May allege the clinic operators submitted claims for services that were either not medically necessary or simply never happened, according to federal prosecutors. That case has become a reference point for a broader concern: unusual and rapid billing increases in states far from Minnesota, a pattern Fox News describes as a "massive red state billing spike" worth watching given the parallels to what investigators found in Minnesota.

As Medicaid dollars flowing into ABA therapy have exploded into the billions nationally, the fraud exposure has grown with it. Autism diagnoses have risen sharply over the past decade, and ABA has become one of the most reimbursed therapies under state Medicaid programs, creating both a genuine treatment need and a bigger target for bad actors.

A Partisan Split Over the Fix

How to respond to that growing exposure is splitting along predictable lines. Florida, a Republican-led state, has prioritized fraud enforcement and tighter oversight of ABA billing. Georgia's debate has instead centered on reimbursement rates and preserving access to care for families who rely on the therapy.

That split mirrors the bigger fight in Washington. The Trump administration has made eliminating fraud, waste and abuse in federal programs, including Medicaid, a stated priority of the president's second term. HHS has already paused more than $1 billion in Medicaid payments to Minnesota and California over fraud and compliance concerns tied to broader program integrity issues, not limited to autism therapy alone.

Supporters of stricter oversight make a straightforward argument: every dollar Medicaid loses to fraudulent billing is a dollar that isn't available for children and families who actually need the care. Autism therapy waitlists exist in many states, and families who are doing everything right to get their kids into legitimate ABA programs have a direct stake in whether fraudulent billing is squeezing out real treatment slots or driving up costs across the system.

The counterargument, raised in states like Georgia, is that crackdowns focused purely on fraud enforcement can create collateral damage. Legitimate providers operating on thin margins can get caught up in slower reimbursement, more paperwork, or payment holds while investigations play out, and families can lose access to therapists in the meantime. Reimbursement rates that don't keep pace with actual costs can also push good providers out of the Medicaid market entirely, leaving fewer options for kids who need care regardless of how fraud enforcement is structured.

What's Actually Been Proven, and What Hasn't

The Minnesota indictments are real, specific, and allege a concrete dollar figure, $46.6 million, tied to named clinic operators and services prosecutors say were fabricated or unnecessary. That's a charged criminal case, not a settled conviction, and the operators are entitled to contest the allegations in court.

The broader claim that other states are seeing suspicious billing spikes resembling Minnesota's pattern is, so far, an inference based on the size and speed of billing increases, not a set of parallel indictments. No criminal charges tied to those other spikes have been announced as of this writing. Treating a billing anomaly as proof of fraud gets the burden of proof backward. It may well be a real problem, but it is not yet a proven one.

The $1 billion in paused Medicaid payments to Minnesota and California is also a compliance and program-integrity action by HHS, not a fraud conviction against those states. States can contest such holds and have in the past.

What's not in dispute is the scale of the money at stake: $5.15 billion in Medicaid spending on a single ABA billing code over six years, with $685 million concentrated in just three providers. Whether that concentration reflects legitimate scale and efficiency or something worth a closer federal audit is the question state Medicaid inspectors general and HHS's Office of Inspector General are now positioned to answer, and neither has yet issued a public report specific to ABA billing patterns nationwide.